Czechs beef up investment in biotech research

The Czech Republic is substantially boosting its investment in biotechnology research, with plans to build a massive research center near Prague set to employ 600 people, the Prague Daily Monitor is reporting. Plans call for spending 2.4 billion crowns (more than $120 million U.S.) on the project, with the investment drawn from EU funds. It will take two years to finish building the complex, which will focus on new drug development, tissue engineering and diagnostics, among other areas. The government plans to pay the researchers high wages and will cover international moving expenses. Construction should start by year-end, according to the article. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.